drugset / Trial / NCT00828204
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
NaSingle-groupOpen-label
Summary
The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).
Timeline
- Start
- 2009-01
- Primary completion
- 2010-07
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon beta-1a | Protein / enzyme biologic | 30 ug | Intramuscular |